- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03732209
A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Participants (N = 64) will be randomly assigned to either an episodic future thinking group or control thinking groups. Participants will generate episodic future events or control information, as well as related text-based cues, and will be prompted via smartphone or web application to engage in episodic future or control thinking frequently in their natural environment (e.g., at home or work, before meal times, and in high-risk situations) for a 4-month period. Participants in both groups will be provided with one-on-one, phone-based case management and provided with instructional materials and behavioral tools for weight loss and diabetes management. Instructional materials will include: 1) a modified version of the Traffic Light Diet, which utilizes red, yellow, and green labels for food to guide participants toward the goal of consuming low energy dense, low glycemic, high nutrient dense foods; 2) the Traffic Light Activity Program, which also utilizes red, yellow, and green labels for different levels of caloric expenditure, and 3) tools for self-monitoring of weight, diet, and/or physical activity.
Participants will complete four laboratory-based assessment sessions in which the investigators assess body weight, height, waist and hip circumference, glycemic control (HbA1C), adherence to oral glucose-lowering medication, delay discounting, reinforcing efficacy of food, and blood pressure. These assessments will be completed before the intervention (Week 0), during the intervention (8 weeks), and immediately after the intervention (Week 16), as well after a 2-month post-intervention follow-up (Week 24). The latter three assessments sessions will also include questions to measure participants' perceived effectiveness and ease of use of the intervention. Participants will also complete several remote assessments, including dietary intake and physical activity (during Weeks 0, 8, and 16; via accelerometer), as well as delay discounting and reinforcing efficacy of food (during Weeks 3, 8, and 16).
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Virginia
-
Roanoke, Virginia, Stati Uniti, 24016
- Fralin Biomedical Research Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Overweight or obese (BMI of 25 or greater)
- Poorly controlled type 2 diabetes (HbA1C of 8% or greater)
- Prescribed or recommended oral glucose-lowering medication
Exclusion Criteria:
- Current insulin therapy for type 2 diabetes
- History of gestational diabetes
- Pregnant or lactating
- Not ambulatory
- Intellectual impairment
- Unmanaged medical or psychiatric disorder
- Abnormal glucose related to medications (e.g, glucocorticoids)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Episodic future thinking
Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
|
Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
|
Comparatore fittizio: Control thinking
Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
|
Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in glycemic control
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Glycemic control will be assessed by hemoglobin A1C (HbA1c), a standardized diagnostic measure for type 2 diabetes.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in weight
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Body weight will be measured using a digital scale.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in delay discounting
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Delay discounting will be assessed using computerized behavioral tasks.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in dietary intake
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Dietary intake will be assessed by 24-hour food recall, using the Automated Self-Administered 24 (ASA-24) food recalls.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in medication adherence
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Medication adherence to oral glucose-lowering medication (e.g., metformin) will be assessed by direct observation (pill counts) and by self-report.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in physical activity
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Duration of physical activity (in minutes) will be measured using an Actigraph accelerometer
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in blood pressure
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Blood pressure will be measured using an automated blood pressure device.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in waist and hip circumference
Lasso di tempo: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Waist and hip circumference will be assessed by measuring tape.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Perceived treatment effectiveness and ease of use
Lasso di tempo: 8 weeks, 16 weeks, and 24 weeks
|
Ease of use and perceived treatment effectiveness for each intervention component will be measured using the Ease of Use and Treatment Effectiveness Questionnaire (EUTEQ), a custom-designed questionnaire modified from a previous scale used in treatment for alcohol use disorder.
Scores will be calculated for each intervention component (e.g., episodic thinking, Traffic Light Diet) separately for ease of use and treatment effectiveness.
Scale ranges from 1 (not at all easy to use/effective) to 5 (very easy to use/effective).
Higher scores represent greater ease of use, perceived effectiveness.
|
8 weeks, 16 weeks, and 24 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Jeff S Stein, PhD, Virginia Tech Carilion School of Medicine and Research Institute
- Investigatore principale: John W Epling, MD, Carilion Clinic
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2696
- 1R21NR018349-01 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Diabete di tipo 2
-
AmgenCompletato
-
Paolo MilaniReclutamentoAmiloidosi | Amiloidosi cardiaca | ATTR Amiloidosi Wild TypeItalia
-
Steen Hvitfeldt PoulsenReclutamentoATTR Amiloidosi Wild TypeDanimarca
-
Oncology Institute of Southern SwitzerlandUniversity of Kiel; Ente Ospedaliero Cantonale, BellinzonaCompletato
-
AmgenCompletatoCancro colorettale metastatico RAS wild-type
-
Henan Cancer HospitalCompletatoCancro colorettale metastatico KRAS, NRAS e BRAF V600E wild-type
-
Austin Neuromuscular CenterAlnylam PharmaceuticalsReclutamentoPolineuropatie | Amiloidosi da transtiretina | Amiloidosi correlata alla transtiretina di tipo selvaggio (ATTR). | Amiloidosi cardiaca da transtiretina wild-type | Amiloidosi ATTR di tipo selvaggioStati Uniti
-
Denver Health and Hospital AuthorityIscrizione su invitoDisturbo evitante restrittivo dell'assunzione di cibo | Anoressia Nervosa, Binge Eating/Purging Type | ARFIDE | Tipo restrittivo di anoressia nervosaStati Uniti
-
Rosemary Claire RodenChildren's Miracle NetworkTerminatoBulimia nervosa | Comportamento impulsivo | Eliminazione (disturbi alimentari) | Problemi alimentari | Disturbi alimentari in adolescenza | Anoressia Nervosa/Bulimia | Anoressia in adolescenza | Anoressia Nervosa, Atipica | Anoressia Nervosa, Binge Eating/Purging TypeStati Uniti
-
Jordan Collaborating Cardiology GroupNon ancora reclutamentoStenosi della valvola aortica | Stenosi aortica grave | ATTR Amiloidosi Wild Type | Studi sul Medio Oriente
Prove cliniche su Episodic future thinking
-
Johns Hopkins UniversityCompletato
-
University of LiverpoolLondon School of Hygiene and Tropical Medicine; National Institute of Mental...Completato
-
Human Development Research Foundation, PakistanUniversity of Liverpool; Shifa Tameer-e-Millat UniversityAttivo, non reclutanteDepressione, dopo il parto | Depressione perinatalePakistan